3174
CSOP China Healthcare Disruption ETF
Solactive China Health Disrupt NR HKD
NAV as of
4 Week: 3.04 - 3.44
52 Week: 2.44 - 3.92
Latest Closing Price
3.16
Premium / Discount
0.13
Expense Ratio
0.99%
Investment Objective
The investment objective of the Sub-Fund is to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Index, namely, Solactive China Healthcare Disruption Index (the “Index”). There is no assurance that the Sub-Fund will achieve its investment objective.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -12.39 | 2.09 | -5.93 |
| 1 Day | -3.86 | 0.00 | 0.00 |
| 1 Week | -1.23 | 5.41 | -0.23 |
| 1 Month | -11.63 | 9.48 | -1.23 |
| 3 Months | -5.71 | 15.87 | -0.36 |
| 6 Months | 10.30 | 30.30 | 0.34 |
| 1 Year | -14.22 | 43.06 | -0.33 |
| 2 Years | 0.00 | 0.00 | 0.00 |
| 3 Years | 0.00 | 0.00 | 0.00 |
| 5 Years | 0.00 | 0.00 | 0.00 |
| 10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
| Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | -27.3472 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 88.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| N.A | ||
Portfolio Data
Total Number of Holdings: 36
Number of Bond Holdings: 0
Number of Equity Holdings: 35
Total Market Value: 31,767,339
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | JD Health International Inc | 9.2140 | 49,070 | 0 | 2,927,026 |
| 2 | Wuxi AppTec Co Ltd | 6.9745 | 29,463 | 0 | 2,215,618 |
| 3 | WuXi Biologics (Cayman) Inc | 6.7760 | 44,845 | 0 | 2,152,560 |
| 4 | CSPC Pharmaceutical Group Ltd | 6.0621 | 241,324 | 0 | 1,925,766 |
| 5 | Shanghai Fosun Pharmaceutical (Group) Co Ltd Class | 5.6092 | 81,365 | 0 | 1,781,894 |
| 6 | Hansoh Pharmaceutical Group Co Ltd | 5.4309 | 118,982 | 0 | 1,725,239 |
| 7 | Sino Biopharmaceutical Ltd | 5.2590 | 380,557 | 0 | 1,670,645 |
| 8 | Alibaba Health Information Technology Ltd | 5.1958 | 273,274 | 0 | 1,650,575 |
| 9 | Innovent Biologics Inc | 4.0561 | 30,900 | 0 | 1,288,530 |
| 10 | Giant Biogene Holding Co Ltd Ordinary Shares | 3.6989 | 20,207 | 0 | 1,175,037 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 22.96 |
| Large | 52.93 |
| Medium | 18.87 |
| Small | 5.04 |
| Micro | 0.00 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
20.9769
Price/Book*
2.7289
Price/Sales*
3.0533
Price/Cash Flow*
17.1022
Dividend Yield*
0.8780
Growth Measures
Long-Term Earnings
15.9975
Historical Earnings
32.3524
Sales Growth
14.5690
Cash-Flow Growth
4.9932
Book-Value Growth
10.2917
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
